Wuhan Healthgen Biotechnology Corp.

Founded in 2006 and based in Wuhan, China, Wuhan Healthgen Biotechnology Corp is a company that focuses on the research and development of Molecular Pharmaceutical. In 2006, the company established OryzHiExp, an expression platform for rice endosperm cells. In 2013, the company completed the preclinical study of OsrHSA. In 2020, the company's plant-derived recombinant human serum albumin injection completed the FIH clinical phase I trial in the United States and entered the international multi-center clinical phase II study.

In December 2014, the company was restructured to become a joint stock company. In October 2025, Wuhan Healthgen Biotechnology Corp raised approximately CNY 2. 60 billion in an IPO, selling 89. 45 million shares at CNY 29.

06 apiece on the Shanghai Stock Exchange (SSE) under the ticker "688765". The company uses rice endosperm cell specific expression platform (OryzHiExp), having high capacity to express proteins or small peptides in the rice grain, to develop the plant-made pharmaceuticals (PMP). The PMP provides a new approach for production of biopharmaceuticals. The company has achievements in developing and commercializing a series of products, including Recombinant Human Serum Albumin (OsrHSA), Recombinant Human basic Fibroblast Growth Factor (OsrhbFGF), Recombinant Human Fibronectin (OsrhFN), Recombinant Human Antitrypsin (OsrhAAT), Recombinant Human Epidermal Growth Factor (OsrhEGF), Recombinant Human Lactoferrin (OsrhLF), Recombinant Human Insulin-like Growth Factor-1 LR3 (rhIGF-1 LR3) ,Recombinant Human Epidermal Growth Factor (rhEGF) and Recombinant Human Fibronectin(OsrhFN).

Meanwhile, it also provides customized protein or peptides expression services. The company generates revenue from developing molecular pharmaceutical products.